<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615142</url>
  </required_header>
  <id_info>
    <org_study_id>ECLIPSE-01</org_study_id>
    <nct_id>NCT05615142</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.</brief_title>
  <official_title>Phase I Study of Low Dose Radiotherapy and Concurrent SBRT in Combination With PD-1 Inhibitors in Advanced Non-small Cell Lung Cancer (NSCLC) .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase I trial aims to investigate the safety and tolerability of low dose&#xD;
      radiotherapy (LDRT) and concurrent partial stereotactic body radiation therapy (SBRT) in&#xD;
      combination with programmed cell death-1 (PD-1) inhibitors in Stage IV non-small cell lung&#xD;
      cancer (NSCLC) patients who have failed standard therapy. At least 14 participants will be&#xD;
      enrolled in this study. All will take part at West China Hospital, Sichuan University.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This exploratory phase I study will be conducted in two steps:&#xD;
&#xD;
      Step A: A dose escalation of low dose radiotherapy (LDRT) and partial SBRT, 3 patients per&#xD;
      cohort (a total of 9 patients) will be enrolled to determine the maximum tolerated dose&#xD;
      (MTD), dose-limiting toxicity (DLT) and recommended dose for expansion (RDE) for lung LDRT&#xD;
      and partial SBRT.&#xD;
&#xD;
      All eligible patients will receive LDRT + partial SBRT at different dose levels (decried as&#xD;
      below), followed by PD-1 inhibitors starting within 7 days after radiation completed. PD-1&#xD;
      inhibitors will be given at doses as recommended in the instruction manual every 3 weeks&#xD;
      until disease progression, unacceptable toxicities, the patient withdraws informed consent,&#xD;
      or PD-1 inhibitors reaches a maximum of up to 48 months.&#xD;
&#xD;
      Patients in the dose escalation will receive LDRT + partial SBRT at 3 cohorts with increasing&#xD;
      dose levels: 2 Gy (2 Gy/f) + 10 Gy (10 Gy/f) in 1 fraction in dose level 1; 4 Gy (2 Gy/f) +&#xD;
      20 Gy (10 Gy/f) in 2 fractions in dose level 2; 6 Gy (2 Gy/f) + 30 Gy (10 Gy/f) in 3&#xD;
      fractions in dose level 3.&#xD;
&#xD;
      Step B: A dose expansion of LDRT + partial SBRT A cohort of 5 patients will receive lung LDRT&#xD;
      and partial SBRT at the RDE determined during the dose escalation phase in combination with&#xD;
      PD-1 inhibitors to obtain additional safety and response data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measurement of Safety and Tolerability of Low Dose Radiotherapy, Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 48 months after the enrollment</time_frame>
    <description>Investigator assessed PFS according to RECIST v1.1. Progression free survival is defined as time of enrollment to first evidence of progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 48 months after the enrollment</time_frame>
    <description>OS is defined as the difference (in months) between the date of study enrollment to the date death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>NSCLC</condition>
  <condition>Low Dose Radiotherapy</condition>
  <condition>Stereotactic Body Radiotherapy</condition>
  <condition>PD-1 Inhibitor</condition>
  <arm_group>
    <arm_group_label>LDRT+SBRT Combined with PD-1 Inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A-Dose escalation cohort. DOSE LEVEL: Low Dose Radiotherapy (LDRT) dose from 2 Gy to 6Gy (2 Gy/f) + partial stereotactic body radiation therapy (SBRT) dose at 10 Gy to 30 Gy (10 Gy/f) + PD-1 inhibitor (dose as recommended in the instruction manual).&#xD;
Part-B - Expansion cohort. LDRT and partial SBRT doses at MTD determined in Part A + PD-1 inhibitor (dose as recommended in the instruction manual).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Low Dose Radiotherapy</intervention_name>
    <description>LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 6 Gy/3f with conventional external beam radiation.</description>
    <arm_group_label>LDRT+SBRT Combined with PD-1 Inhibitors</arm_group_label>
    <other_name>LDRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy</intervention_name>
    <description>Partial SBRT at dose escalation levels: 10 Gy/1f, 20 Gy/2f, 30 Gy/3f.</description>
    <arm_group_label>LDRT+SBRT Combined with PD-1 Inhibitors</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 Inhibitors</intervention_name>
    <description>Patients will receive treatment with PD-1 inhibitor (dose as recommended in the instruction manual) every 3 weeks for a maximum of 48 months.</description>
    <arm_group_label>LDRT+SBRT Combined with PD-1 Inhibitors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
          2. Be ≥18 years of age on day of signing informed consent.&#xD;
&#xD;
          3. Patients with histologically or cytologically confirmed stage IV NSCLC.&#xD;
&#xD;
          4. Be willing to undergo repeat biopsy of tumor lesions according to the study protocol.&#xD;
&#xD;
          5. Patients who have failed the standard therapy, or who are unsuitable for standard&#xD;
             treatment, or refuse chemotherapy.&#xD;
&#xD;
          6. At least one measurable lesion according to RECIST 1.1. A lesion that has previously&#xD;
             received radiotherapy can be considered a target lesion only if this lesion is clearly&#xD;
             progressed after radiotherapy.&#xD;
&#xD;
          7. The target lesions (irradiated lesions) are &gt; 5cm in in diameter&#xD;
&#xD;
          8. ECOG 0-2.&#xD;
&#xD;
          9. Life expectancy of &gt; 3 months.&#xD;
&#xD;
         10. Patients must have normal organ and bone marrow function as defined below: Total&#xD;
             bilirubin &lt;/= 1.5 x upper limit of normal (ULN). Aminotransferase (AST) Serum Glutamic&#xD;
             Oxaloacetic Transaminase (SGOT)/ Alanine Aminotransferase (ALT) Serum Glutamic-Pyruvic&#xD;
             Transaminase (SGPT) &lt;2.5 X institutional upper limit of normal (&lt;/= 5 X institutional&#xD;
             ULN for subjects with liver metastases) *WBC &gt;/= 3500/uL, ANC &gt;/= 1500/uL *Platelets&#xD;
             &gt;/= 90K/ul *Hemoglobin &gt;/= 9g/dL *Creatinine &lt;/= 1.5 x ULN, or creatinine clearance ≥&#xD;
             50 ml/min（Cockcroft-Gault equation）. Coagulation: International Normalized Ratio&#xD;
             (INR)≤ 1.5 × ULN, Partial thromboplastin time (PTT) ≤1.5 × ULN; left ventricular&#xD;
             ejection fraction (LVEF) &gt;/= 50% and QTcF (Fridericia's formula) ≤ 450ms&#xD;
&#xD;
         11. Patients has recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a&#xD;
             previously administered agent.&#xD;
&#xD;
         12. Wash out period for chemotherapy is more than ≥ 4 weeks, for targeted small molecule&#xD;
             therapy ≥ 5 half-lives; palliative radiotherapy must have been completed for at least&#xD;
             ≥ 2 weeks, chest radiotherapy must have been completed for at least ≥ 4 weeks, and&#xD;
             major surgery must have been completed for ≥ 4 weeks.&#xD;
&#xD;
         13. Subjects with no severe pulmonary ventilation dysfunction, no acute heart failure, and&#xD;
             no contraindication to radiotherapy as judged by the radiotherapist. Subjects who&#xD;
             agree to receive immunotherapy and radiotherapy treatment.&#xD;
&#xD;
         14. Subjects should agree to use an adequate method of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis and/or spinal cord compression, etc.&#xD;
&#xD;
          2. With oncologic emergencies that require immediate treatment&#xD;
&#xD;
          3. EGFR/ALK/ROS-1 mutation or mutation status unknown.&#xD;
&#xD;
          4. Has evidence of interstitial lung disease or active and/or non-infectious pneumonitis&#xD;
             (drug-induced pneumonia, radiation-induced pneumonia, etc.) requiring steroid therapy.&#xD;
&#xD;
          5. History of pulmonary fibrosis, pulmonary hypertension, severe irreversible airway&#xD;
             obstruction disease&#xD;
&#xD;
          6. Patients with peripheral neuropathy.&#xD;
&#xD;
          7. Significant heart disease or impairment of cardiac function&#xD;
&#xD;
          8. Fluid accumulating in the third space, such as pericardial effusion, pleural effusion&#xD;
             and peritoneal effusion that remains uncontrolled by aspiration or other treatment&#xD;
&#xD;
          9. Known allergy to drugs or excipients, known severe allergic reaction to any of the&#xD;
             PD-1 monoclonal antibodies&#xD;
&#xD;
         10. Severe infection within 4 weeks prior to the start of study treatment, including but&#xD;
             not limited to hospitalization for infection, bacteremia, or severe pneumonia;&#xD;
             treatment with oral or intravenous antibiotics within 2 weeks prior to the start of&#xD;
             study treatment; patients receiving prophylactic antibiotic therapy (e.g., to prevent&#xD;
             urinary tract infection or exacerbation of COPD) are eligible for this study.&#xD;
&#xD;
         11. Known or suspected active autoimmune disease (congenital or acquired) such as uveitis,&#xD;
             enterocolitis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroiditis,&#xD;
             etc. (patients with vitiligo, or resolved childhood asthma may be enrolled; patients&#xD;
             with type I diabetes with good insulin control may also be enrolled)&#xD;
&#xD;
         12. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic&#xD;
             hematopoietic stem cell transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>You Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>You Lu, MD</last_name>
    <phone>18980601763</phone>
    <phone_ext>+86</phone_ext>
    <email>radyoulu@hotmali.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ren Luo, MD</last_name>
    <phone>18349337131</phone>
    <phone_ext>+86</phone_ext>
    <email>luorenbu@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ren Luo, MD</last_name>
      <phone>18349337131</phone>
      <phone_ext>+86</phone_ext>
      <email>luorenbu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172.</citation>
    <PMID>25838373</PMID>
  </reference>
  <reference>
    <citation>Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer. 2016 Jun;2(6):286-294. doi: 10.1016/j.trecan.2016.05.002.</citation>
    <PMID>27774519</PMID>
  </reference>
  <reference>
    <citation>Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016 Aug;13(8):516-24. doi: 10.1038/nrclinonc.2016.30. Epub 2016 Mar 8.</citation>
    <PMID>26951040</PMID>
  </reference>
  <reference>
    <citation>Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryan WF, Garces YI, Pu AT, Singh AK, Videtic GM, McGarry RC, Iyengar P, Pantarotto JR, Urbanic JJ, Sun AY, Daly ME, Grills IS, Sperduto P, Normolle DP, Bradley JD, Choy H. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol. 2019 May 20;37(15):1316-1325. doi: 10.1200/JCO.18.00622. Epub 2019 Apr 3.</citation>
    <PMID>30943123</PMID>
  </reference>
  <reference>
    <citation>Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, Klapproth K, Schakel K, Garbi N, Jager D, Weitz J, Schmitz-Winnenthal H, Hammerling GJ, Beckhove P. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013 Nov 11;24(5):589-602. doi: 10.1016/j.ccr.2013.09.014. Epub 2013 Oct 24.</citation>
    <PMID>24209604</PMID>
  </reference>
  <reference>
    <citation>Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, Monkhorst K, Baas P. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Sep 1;5(9):1276-1282. doi: 10.1001/jamaoncol.2019.1478.</citation>
    <PMID>31294749</PMID>
  </reference>
  <reference>
    <citation>Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, Orcurto A, Imbimbo M, Ghisoni E, Navarro Rodrigo B, Berthold DR, Sarivalasis A, Zaman K, Duran R, Dromain C, Prior J, Schaefer N, Bourhis J, Dimopoulou G, Tsourti Z, Messemaker M, Smith T, Warren SE, Foukas P, Rusakiewicz S, Pittet MJ, Zimmermann S, Sempoux C, Dafni U, Harari A, Kandalaft LE, Carmona SJ, Dangaj Laniti D, Irving M, Coukos G. Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discov. 2022 Jan;12(1):108-133. doi: 10.1158/2159-8290.CD-21-0003. Epub 2021 Sep 3.</citation>
    <PMID>34479871</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 11, 2022</last_update_submitted>
  <last_update_submitted_qc>November 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>You Lu</investigator_full_name>
    <investigator_title>Chair of Department of Thoracic Cancer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

